AKT1 and neoplasm: In neuroblastoma, BBR treatment was able to induce the expression of epithelial-like marker E-cadherin, downregulating crucial signaling pathways that regulate tumor progression, such as PI3K/Akt, TGF-β, and MAPK [146].